D.A. Davidson & CO. Purchases 91,438 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

D.A. Davidson & CO. lifted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) by 571.7% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 107,432 shares of the company's stock after purchasing an additional 91,438 shares during the period. D.A. Davidson & CO.'s holdings in Recursion Pharmaceuticals were worth $568,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the business. Kinnevik AB publ increased its position in Recursion Pharmaceuticals by 12.8% in the first quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock worth $71,067,000 after buying an additional 1,528,503 shares in the last quarter. Clear Creek Financial Management LLC grew its stake in shares of Recursion Pharmaceuticals by 9.8% during the 1st quarter. Clear Creek Financial Management LLC now owns 21,315 shares of the company's stock valued at $113,000 after acquiring an additional 1,907 shares during the period. PDS Planning Inc purchased a new stake in Recursion Pharmaceuticals in the 1st quarter worth approximately $69,000. Sequoia Financial Advisors LLC bought a new stake in Recursion Pharmaceuticals during the 1st quarter worth approximately $67,000. Finally, Cambridge Investment Research Advisors Inc. lifted its holdings in Recursion Pharmaceuticals by 33.1% during the first quarter. Cambridge Investment Research Advisors Inc. now owns 117,120 shares of the company's stock valued at $620,000 after purchasing an additional 29,136 shares in the last quarter. Hedge funds and other institutional investors own 89.06% of the company's stock.

Recursion Pharmaceuticals Stock Performance

RXRX remained flat at $5.28 during trading on Monday. 20,298,686 shares of the company's stock were exchanged, compared to its average volume of 16,623,335. The stock has a market capitalization of $2.15 billion, a P/E ratio of -2.98 and a beta of 0.91. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. Recursion Pharmaceuticals, Inc. has a twelve month low of $3.79 and a twelve month high of $12.36. The business's 50-day simple moving average is $4.82 and its two-hundred day simple moving average is $6.03.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its earnings results on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). The company had revenue of $14.75 million for the quarter, compared to analysts' expectations of $18.12 million. Recursion Pharmaceuticals had a negative net margin of 961.32% and a negative return on equity of 74.70%. The business's revenue was up 7.2% on a year-over-year basis. During the same period in the previous year, the business posted ($0.39) earnings per share. As a group, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on RXRX. Morgan Stanley initiated coverage on shares of Recursion Pharmaceuticals in a research note on Thursday, July 3rd. They issued an "equal weight" rating and a $5.00 price objective for the company. Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price target on shares of Recursion Pharmaceuticals in a research note on Tuesday, July 8th. Four research analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $7.00.

Recursion Pharmaceuticals Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.